Dominik Paul Modest

Health-related quality of life in patients with KRASG12C-mutated chemo... sciencedirect.com/science/articl…

@richardashcroft @NocturneLive Surprised by the joy Hold on Sonnet On a beach Life’s an ocean Song for the lovers Break the night Beatitudes Lucky man They don’t own me Lover Love is noise BSS

Only 3 days until Richard plays @NocturneLive at Blenheim Palace. What's on your dream set list?

🚨 #LowerGIcancer highlights from #ASCO24 🚨 Prof. @JenSeligmann & Dr @ModestDominik share their views on new data from #COLLISION & #TRANSMET trials presented at the congress. ⬇️🎥⬇️ #MedEd #ASCOhighlights #CRCSM #LowerGI

🚨#LowerGIcancer highlights from #ASCO24🚨 Medical oncologists Prof. @JenSeligmann and Dr @ModestDominik share their views on new data in #rectalcancer and #CRC from the NEOPRISM-CRC trial & LBA3512. Watch the video 📺 👇 #MedEd #oncology #CRCSM

Voting open for @myESMO #president 2027-2028! Vote now, or on your way to #ASCO24! My vote 👇 @Prof_Nadia_H #mentor #strong #womenleaders #femalepresident

Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) nej.md/3M8Qw3k #ESMO23 #oncology

@YJanjigianMD @MSKCancerCenter @MSK_DeptOfMed @debschrag @OncoAlert Congrats to important study… a paradigm for patients sure to undergo surgery. Who are these patients? Or is TNT without surgery the way in these moderately advanced tumors the way? I find it more difficult than the NYT does 😂. I agree with the discussant it is an option…

Practice changing study by @MSKCancerCenter @MSK_DeptOfMed Chair @debschrag & colleagues. @OncoAlert nejm.org/doi/full/10.10… nytimes.com/2023/06/04/hea…

Five @giconnectInfo experts provide a handy update from #ESMO2022! ➡️ Podcast Ep. 1: Lower #GIcancer highlights ➡️ Podcast Ep. 2: Upper #GIcancer highlights ➡️ Video summary of NICHE-2 trial For the podcasts, video and downloadable content, follow: ow.ly/6GQF50L2EhI #MedEd

💥💥💥💥@MyriamChalabi #ESMO22 discussing NICHE2 - neoadjuvant nivo/ipi in locally advanced colon cancer 💥short duration safe pre-op 💥4% grade 3 events 💥100% R0 resection 💥95% major path; 67% pCR …round of applause in session! 1/2

@alarjosan But promoting this without effect on DFS and OS… I am not up for it. Needs more effect for the overall population. Saying this as surgery-passionate oncologist

@ModestDominik Agree our purpose is to control the peritoneal disease , for systemic we trust on chemo

Great to see randomized data. Congratulations!! Great achievement. Final conclusion (do it or not) more complex. Data suggest that HIPEC influences local but not systemic control and systemic relapse is a frequent issue.

Niche-2. No need for further interpretation… congrats to Myriam!! What a perfect presentation of a super trial. Great that we had a wowww moment in colon cancer.

Well said @FilippoPietran4 …and @myESMO #ESMO22 is approaching fast!

Proud to present our subgroup analysis of the PANAMA-study according to #gender and age in patients with #colorectalcancer at #ASCO2022! Thanks to my amazing mentors @ModestDominik and @StintzingS for their support!

The protocol of the PORT trial is published, which aims to generate evidence that post-resection/ablation/radiation chemotherapy improves the survival in patients with metastatic colorectal cancer. bmccancer.biomedcentral.com/articles/10.11… @ModestDominik @Sauer_et_al

@JenSeligmann @MyriamChalabi Who was this? Always keen on learning what to avoid?

@MyriamChalabi Recent experience, 4 months for review then rejected despite positive comments. Confirmed ‘rejected in error’ invited to re-submit (after 6/52 wait) 2 months more review then transferred to sister journal 🤬🤬🤬needless to say didn’t take them up on kind offer

Manuscript submitted: October 31st. No decision nor communication from journal, despite reminder 3 weeks ago (I would say I’ve been very patient). What would you do? And what is acceptable?

@MyriamChalabi @JenSeligmann Maybe you just need nicer reviewers😂

@JenSeligmann Sounds like a reason to 🏷😡!

Our new podcast series is out! In Episode 2 @JenSeligmann, @McreeAutumn and @ModestDominik are discussing #immunotherapy approaches! Listen to the podcast and download the transcript at: ow.ly/erC950GKbN6 #MedEd #GI #GC

Eine interdisziplinäre klinische Studie zur Therapie von #Darmkrebs startet nun unter Leitung der #CharitéBerlin. Die FIRE-9/PORT-Studie soll helfen, die Neuentstehung von Metastasen zu verhindern. @ModestDominik @StintzingS @AIO_Onkologie @LMU_Uniklinikum charite.de/service/presse…

@pashtoonkasi @realbowtiedoc @JenSeligmann @myESMO @OncoAlert I do hope that all options for local therapies were evaluated before random in Panama (consort diagram). Staying pragmatic: do maintenance if needed, switch to 2nd line afterwards…

@realbowtiedoc @JenSeligmann @ModestDominik @realbowtiedoc @JenSeligmann EGFR/RAS/RAF/HER2 🟠🟡🔴clones emerge & predate progression/mixed responses on scans. While still a subject of #clinicaltrials, reasonable to consider #ctDNA & either switch or consider locoregional. #ESMO21 @myESMO @OncoAlert EGFR♻️ later an option.

More data re maintenance #CRCSM PANAMA trial ⁦@ASCO_pubs⁩ ⁦@OncoAlert⁩ FU +/- panitimumab post induction ctx in RAS-wt: 1/2 ✅ ⬆️PFS with pan; 8.8 vs 5.7. Primary endpoint ↔️ OS ?immature/sample size vs ⬇️effect of reinduction rx in pan arm ascopubs.org/doi/full/10.12…